On-Demand WebinarChemotherapy-induced peripheral neuropathy (CIPN) is a common neurological complication associated with widely prescribed chemotherapeutics, such as microtubule inhibitors (MTis). Antibody-drug conjugates (ADCs) are an innovative class of cancer therapeutics designed to target cytotoxic payloads, including MTis, directly to cancer cells with the aim of increasing the therapeutic window of their payload.To aid pre-clinical in vitro toxicity evaluation of drug compounds, we developed a robust model to study neurite outgrowth and damage in 3D and demonstrate that MTis of different chemistry classes induce neurite damage. Importantly, the model’s pre-clinical relevance is reflected by its ability to capture neurite damage induced by ADCETRIS®, a clinically approved ADC known to cause CIPN in clinical settings.Watch our on-demand webinar to learn how this model has the potential to be utilized as a tool to predict neurotoxic effects of novel ADCs to enable safety predictions at early stages in the development process.Webinar highlights:
- Learn about comprehensive 3D in vitro modeling of nerve damage induced by MTi chemotherapeutics
- Explore how our developed model may be used as a tool to better investigate the toxicity of ADCs
- Discover how partnering with MIMETAS can aid in your drug discovery, mitigating toxic side-effects of compounds and yielding better future treatments